SG10201704467SA - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SG10201704467SA
SG10201704467SA SG10201704467SA SG10201704467SA SG10201704467SA SG 10201704467S A SG10201704467S A SG 10201704467SA SG 10201704467S A SG10201704467S A SG 10201704467SA SG 10201704467S A SG10201704467S A SG 10201704467SA SG 10201704467S A SG10201704467S A SG 10201704467SA
Authority
SG
Singapore
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
SG10201704467SA
Other languages
English (en)
Inventor
Shenshen Cai
Brian Alvin Johns
Andrew Spaltenstein
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SG10201704467SA publication Critical patent/SG10201704467SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
SG10201704467SA 2012-12-14 2013-12-14 Pharmaceutical compositions SG10201704467SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737177P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
SG10201704467SA true SG10201704467SA (en) 2017-06-29

Family

ID=50935020

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201503807TA SG11201503807TA (en) 2012-12-14 2013-12-14 Pharmaceutical compositions
SG10201704467SA SG10201704467SA (en) 2012-12-14 2013-12-14 Pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201503807TA SG11201503807TA (en) 2012-12-14 2013-12-14 Pharmaceutical compositions

Country Status (20)

Country Link
US (2) US9795619B2 (enExample)
EP (1) EP2931285A4 (enExample)
JP (1) JP2016503030A (enExample)
KR (1) KR20150093819A (enExample)
CN (1) CN104902905A (enExample)
AU (1) AU2013358897B2 (enExample)
BR (1) BR112015013695A2 (enExample)
CA (1) CA2893959A1 (enExample)
CL (1) CL2015001660A1 (enExample)
CR (1) CR20150313A (enExample)
EA (1) EA201590862A1 (enExample)
HK (1) HK1209638A1 (enExample)
IL (1) IL238807A0 (enExample)
MA (1) MA38182A1 (enExample)
MX (1) MX2015007563A (enExample)
PE (1) PE20151326A1 (enExample)
PH (1) PH12015501156A1 (enExample)
SG (2) SG11201503807TA (enExample)
WO (1) WO2014093941A1 (enExample)
ZA (1) ZA201503594B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
SG11201503807TA (en) * 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
LT3019503T (lt) 2013-07-12 2017-11-27 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
NO2865735T3 (enExample) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
CA2961528A1 (en) * 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2018042331A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
EP1292562A1 (en) 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenoid derivatives
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN1682740A (zh) * 2005-03-11 2005-10-19 中国药科大学 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用
US20090023698A1 (en) 2005-03-29 2009-01-22 Krasutsky Pavel A Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Hiv-感染之預防
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
JP2009527563A (ja) 2006-02-21 2009-07-30 アキリオン ファーマシューティカルズ,インコーポレーテッド ウイルス感染症を治療するのに有用な置換タラキサスタン
FI121468B (fi) 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset yhdisteet antimikrobisina aineina
SI3366278T1 (sl) 2006-06-23 2024-12-31 Janssen Sciences Ireland Unlimited Company Vodne suspenzije tmc278
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
AR063546A1 (es) 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
DK2175857T3 (da) * 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
EP2250185A4 (en) 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ2008723A3 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
EP2376080B1 (en) * 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
MX2012009319A (es) * 2010-02-11 2012-09-12 Glaxosmithkline Llc Derivados de betulina.
TWI577377B (zh) * 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
JP6091520B2 (ja) 2011-12-14 2017-03-08 グラクソスミスクライン エルエルシー ベツリンのプロペン酸誘導体
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
US20150209273A1 (en) 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
SG11201503807TA (en) * 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
CA2961528A1 (en) 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions

Also Published As

Publication number Publication date
CL2015001660A1 (es) 2015-10-02
EA201590862A1 (ru) 2016-05-31
CN104902905A (zh) 2015-09-09
MA38182A1 (fr) 2018-04-30
CA2893959A1 (en) 2014-06-19
ZA201503594B (en) 2018-11-28
EP2931285A1 (en) 2015-10-21
BR112015013695A2 (pt) 2017-07-11
HK1209638A1 (en) 2016-04-08
SG11201503807TA (en) 2015-06-29
US20150313917A1 (en) 2015-11-05
JP2016503030A (ja) 2016-02-01
US9795619B2 (en) 2017-10-24
AU2013358897B2 (en) 2017-01-05
MX2015007563A (es) 2015-10-14
EP2931285A4 (en) 2016-06-01
AU2013358897A1 (en) 2015-07-02
KR20150093819A (ko) 2015-08-18
PE20151326A1 (es) 2015-10-12
WO2014093941A1 (en) 2014-06-19
CR20150313A (es) 2015-10-19
PH12015501156A1 (en) 2015-08-10
IL238807A0 (en) 2015-06-30
US20180042944A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
ZA201703992B (en) Inhalable pharmaceutical compositions
GB201113662D0 (en) Pharmaceutical compositions
ZA201503594B (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
ZA201308208B (en) Pharmaceutical compositions
ZA201407373B (en) Novel pharmaceutical formulations
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
IL266415A (en) Innovative pharmaceutical composition
GB201201287D0 (en) Compositions
GB201118181D0 (en) Pharmaceutical compositions
ZA201502987B (en) Pharmaceutical composition
GB201211153D0 (en) Pharmaceutical compositions
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS